Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Pilar Hernandez-Campo"'
Autor:
Fermin M. Sanchez-Guijo M.D., PhD., Enrique Oterino, Maria-Victoria Barbado, Soraya Carrancio, Natalia Lopez-Holgado, Sandra Muntion, Pilar Hernandez-Campo, Luis-Ignacio Sanchez-Abarca, Jose A. Perez-Simon, Jesús F. San Miguel, Jesús G. Briñon, Maria-Consuelo Del Cañizo
Publikováno v:
Cell Transplantation, Vol 19 (2010)
To address a number of questions regarding the experimental use of bone marrow (BM) stem cells in hindlimb ischemia, including which is the best cell type (e.g., purified hematopoietic stem cell or monocytes), the best route of delivery [intramuscula
Externí odkaz:
https://doaj.org/article/3522c668bf25430da12d017ff76af41c
Autor:
María Luz Morales, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Julian Gorrochategui, Inmaculada Rapado, Miguel Gallardo, Pilar Hernandez-Campo, Alicia Arenas Cortés, Daniel Primo, María Linares, Joan Ballesteros, Alicia Robles
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Haematologica
Instituto de Salud Carlos III (ISCIII)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Haematologica
Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09272106ec2b40fb6b252f6b76479820
http://hdl.handle.net/20.500.12105/9333
http://hdl.handle.net/20.500.12105/9333
Autor:
Pilar Hernandez-Campo, Alberto Orfao, Lourdes Martín-Martín, Maria Luz Sanchez, Quentin Lecrevisse, Julia Almeida
Publikováno v:
Transfusion. 49:1692-1708
BACKGROUND: Information about maturation of plasmacytoid dendritic cell precursors (pre-pDCs) in normal bone marrow (BM) remains limited. STUDY DESIGN AND METHODS: Immunophenotypical, morphologic, and functional changes associated with maturation of
Autor:
Natalia Lopez-Holgado, Fermín Sánchez-Guijo, Maria-Victoria Barbado, Pilar Hernandez-Campo, Jesús M. Hernández-Rivas, Cristina Robledo, Olga López-Villar, Jesús F. San-Miguel, Eva Villarón, M-C del Cañizo, Juan Luis García, María Díez-Campelo, José A. Pérez-Simón
Publikováno v:
Leukemia. 23:664-672
The presence of cytogenetic aberrations on mesenchymal stem cells (MSC) from myelodysplastic syndrome (MDS) patients is controversial. The aim of the study is to characterize bone marrow (BM) derived MSC from patients with MDS using: kinetic studies,
Autor:
Ignacio Alberca, Maria Luz Sanchez, Pilar Hernandez-Campo, Alberto Orfao, María Jara Acevedo, Belén Vidriales, Elvira Martínez, Juan R Romero, Julia Almeida
Publikováno v:
Transfusion. 48:1403-1414
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by a deficient expression of glycosylphosphatidylinositol-anchored proteins (GPI-APs), due to somatic mutations of the phosphatidylinositolglycan complementation Class A (PIG-A) g
Autor:
J M Sayagués, Pilar Hernandez-Campo, J.M. Hernández Rivas, Maria-Luz Sanchez, Sergio Matarraz, Luis Perdiguer, Juan Flores, Nuria Fernandez-Mosteirin, A. López, Alberto Orfao, Carlos Salvador, C Fernandez, Susana Barrena, Evan Jensen, Ana Rasillo, Paloma Bárcena, Manuel Giralt
Publikováno v:
Leukemia. 22:1175-1183
Occurrence of phenotypic abnormalities in CD34(+) hematopoietic progenitor and precursor cells (HPC) and their major B-cell and nonlymphoid compartments has been frequently reported in myelodysplastic syndromes (MDS). Here, we analyze for the first t
Autor:
Pilar Hernandez-Campo, Alberto Orfao, Sergio Matarraz, Maria Luz Sanchez, María de Santiago, Julia Almeida
Publikováno v:
Cytometry Part B: Clinical Cytometry. :34-42
Background: Glycosylphosphatidylinositol-anchored proteins (GPI-AP) are a heterogeneous group of proteins deficiently expressed in patients with paroxysmal nocturnal hemoglobinuria. Up till now, no study has been reported in which the exact patterns
Publikováno v:
Cytometry. 50:191-201
BACKGROUND Flow cytometry-based immunophenotypic techniques for the analysis of CD55 and CD59 expression on the major cell populations present in blood are the preferred method for the diagnostic screening of paroxysmal nocturnal hemoglobinuria (PNH)
Autor:
David Martínez-Cuadrón, Miguel A. Sanz, Jose Angel Hernandez Rivas, Julian Gorrochategui, Carmen Burgaleta, A. González, Pilar Hernandez-Campo, Alvaro Janda, Jaime Pérez de Oteyza, Teresa Bennett, Consolación Rayón, Belen Liebana, Arancha Alonso, Santiago Leguey Jiménez, Andrew G. Bosanquet, Angeles Fernandez, Pilar Herrera, Juan Antonio López, Rocío López, Iñaki F. Trocóniz, Pascual Fernández, Joan Ballesteros, Jorge Sierra, Josefina Serrano, Adriana Simiele, Joaquín Martínez, Raul Cordoba Mascuñano, Raimundo García, Gabriela Rodríguez-Macías, Daniel Primo, Begoña Navas, Guiomar Bautista, Juan Antonio Vera, Belén Vidriales, Bernardo Gonzalez, Pau Montesinos, José Luis Rojas, Concepcion Bethancourt, Federico Moscardó, Esperanza Lavilla, Adolfo de la Fuente, Jose Antonio Pérez Simón
Publikováno v:
Clinical Lymphoma Myeloma & Leukemia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
We have estimated the pharmacological sensitivity and synergism of 125 individual patient samples for all drugs and combination treatments for acute myeloid leukemia in the context of the overall patient population. Each ex vivo pharmacological profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67780eddde3721e7b4f688b9581b255
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9205
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=9205
Autor:
Mercedes Garayoa, Juan F. Blanco, Jesús G. Briñón, Edvan de Queiroz Crusoe, Teresa Hernández-Iglesias, Francis Y. Lee, Pilar Hernandez-Campo, Jesús F. San Miguel, Carlos Santamaría, Rosa M. Fisac-Herrero, Atanasio Pandiella, Enrique M. Ocio, Fermín Sánchez-Guijo, Antonio Garcia-Gomez
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34914 (2012)
Digital.CSIC. Repositorio Institucional del CSIC
instname
PLoS ONE
Digital.CSIC. Repositorio Institucional del CSIC
instname
PLoS ONE
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.
[Background]: Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteobl
[Background]: Bone loss, in malignant or non-malignant diseases, is caused by increased osteoclast resorption and/or reduced osteobl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f8e85d36fd8fdcaa488278e0aa10dc6
http://hdl.handle.net/10261/60019
http://hdl.handle.net/10261/60019